Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The user is using a hair loss treatment involving dutasteride, minoxidil, finasteride, microneedling, and supplements like multivitamins, D3 K2, and Omega 3 fish oil. They are considering adding tretinoin and are open to suggestions while managing gut issues.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Most people using finasteride, minoxidil, or dutasteride for hair loss experience maintenance or regrowth, but they often don't discuss it publicly. Online forums may not accurately represent the typical success rates, as satisfied users rarely share their positive outcomes.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The conversation is about seeking user experiences with Traya for hair loss treatment, focusing on the effectiveness and convenience of its doctor, diet, and product approach. The user is conducting research and requests feedback on what worked or didn't work.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.

The conversation is about using topical finasteride for hair loss and concerns about its application, side effects, and practicality. Users suggest switching to oral finasteride for convenience, despite potential side effects.

Finasteride treatment is being considered, and it's advised to track DHT, testosterone, estradiol, and SHBG levels to monitor hormonal changes. These tests will help understand the treatment's impact.

Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.

A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The user is concerned about post-hair transplant care, specifically regarding the use of a bandana, minoxidil, and tretinoin. They are advised to consider finasteride and possibly adjust the minoxidil dosage.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

People discuss whether it's appropriate to suggest hair loss treatments like finasteride or minoxidil to others, especially young individuals. Opinions vary, with some advocating for sharing information and others cautioning against unsolicited advice due to potential side effects and personal sensitivities.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

The conversation is about a user making a homemade topical dutasteride solution to use alongside testosterone replacement therapy (TRT) and oral dutasteride. The user aims to reduce DHT locally at the testosterone injection site and on the scalp.